Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets  by Chen, Grace L. et al.
Virology 398 (2010) 109–114
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roSafety, immunogencity, and efﬁcacy of a cold-adapted A/Ann Arbor/6/60 (H2N2)
vaccine in mice and ferrets
Grace L. Chen a, Elaine W. Lamirande a, Hong Jin b, George Kemble b, Kanta Subbarao a,⁎
a Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA
b Medimmune, Mountain View, CA 94043, USA⁎ Corresponding author. Laboratory of Infectious Disea
3E13C.1, 33 North Drive, MSC 3203, Bethesda, MD 2089
5722.
E-mail addresses: chengra@niaid.nih.gov (G.L. Chen)
(E.W. Lamirande), jinh@medimmune.com (H. Jin), kem
(G. Kemble), ksubbarao@niaid.nih.gov (K. Subbarao).
0042-6822/$ – see front matter. Published by Elsevier
doi:10.1016/j.virol.2009.12.003a b s t r a c ta r t i c l e i n f oArticle history:
Received 28 August 2009
Returned to author for revision
18 September 2009
Accepted 1 December 2009
Available online 24 December 2009
Keywords:
Live attenuated inﬂuenza vaccines
A/Ann Arbor/6/60 (H2N2)We studied the attenuation, immunogenicity and efﬁcacy of the cold-adapted A/Ann Arbor/6/60 (AA ca)
(H2N2) virus in mice and ferrets to evaluate its use in the event of an H2 inﬂuenza pandemic. The AA ca virus
was restricted in replication in the respiratory tract of mice and ferrets. In mice, 2 doses of vaccine elicited
a N4-fold rise in hemagglutination–inhibition (HAI) titer and resulted in complete inhibition of viral
replication following lethal homologous wild-type virus challenge. In ferrets, a single dose of the vaccine
elicited a N4-fold rise in HAI titer and conferred complete protection against homologous wild-type virus
challenge in the upper respiratory tract. In both mice and ferrets, the AA ca virus provided signiﬁcant
protection from challenge with heterologous H2 virus challenge in the respiratory tract. The AA ca vaccine is
safe, immunogenic, and efﬁcacious against homologous and heterologous challenge in mice and ferrets,
supporting the evaluation of this vaccine in clinical trials.
Published by Elsevier Inc.Background
Inﬂuenza A viruses are categorized into subtypes based on the
hemagglutinin (HA) and neuraminidase (NA) surface proteins.
Seasonal inﬂuenza epidemics arise from antigenic drift due to point
mutations in the genes encoding the surface proteins within a
circulating subtype. In contrast, inﬂuenza pandemics arise from
antigenic shift during which a new HA with or without a new NA is
introduced into a population with little preexisting immunity to the
new subtype (Wright et al., 2007). A lack of preexisting immunity to
the new subtype can result in substantially higher morbidity and
mortality rates during inﬂuenza pandemics compared with epi-
demics. During the pandemics of the last century, mortalities are
estimated to be at least 20 million from H1N1 inﬂuenza in 1918
(Crosby, 1976) and approximately 1 million following the H2N2
pandemic in 1957 and over 500,000 as a result of H3N2 in 1968
(Potter, 1998).
Pandemic inﬂuenza preparedness planning has focused on highly
pathogenic H5 and H7 avian inﬂuenza viruses. However, the recent
emergence of the novel swine-origin H1N1 inﬂuenza virus empha-
sizes the need to include other inﬂuenza subtypes in pandemic
preparedness planning. Several factors contribute to the possibility ofses, NIAID, NIH, Bldg 33, Room
2-3203, USA. Fax: +1 301 480
, elamirande@niaid.nih.gov
bleg@medimmune.com
Inc.an H2 inﬂuenza pandemic. First, H2 viruses have proven capable of
causing disease in humans. Of the sixteen HA and nine NA subtypes,
only H1, H2, and H3 viruses have been known to lead to human
inﬂuenza pandemics since inﬂuenza viruses were ﬁrst isolated in
1933 (Dowdle, 1999; Potter, 1998). While H1N1 and H3N2 viruses
have been cocirculating for the past 30 years, H2N2 viruses have not
circulated in humans since 1968 (Cox and Subbarao, 2000). Thus,
there is declining preexisting immunity to H2 inﬂuenza viruses in the
population today.
Although H2 inﬂuenza has not circulated in humans since 1968,
this subtype is maintained in avian reservoirs worldwide (Jonassen
and Handeland, 2007; Kishida et al., 2008; Krauss et al., 2007;
Makarova et al., 1999; Suss et al., 1994). Waterfowl and shorebirds
have been the primary source of novel HAs from which pandemic
inﬂuenza strains have emerged (Webster et al., 1992); genetic
characterization of the newly emerged H1N1 inﬂuenza virus suggests
that it originated from pigs (Garten et al., 2009; Neumann et al., 2009).
H2N2 viruses that caused the 1957 pandemic were derived from a
reassortment of the HA, NA, and PB1 genes from an avian H2 virus
with a contemporary H1N1 human inﬂuenza virus (Kawaoka et al.,
1989; Scholtissek et al., 1978). There is evidence that inﬂuenza viruses
in aquatic birds are in evolutionary stasis (Gorman et al., 1992), and as
a consequence, it is likely that the viruses that were the source of gene
segments for previous pandemics, including the H2N2 virus, continue
to circulate and thus pose an ongoing risk of reemergence (Schafer et
al., 1993;Webster, 1997). The continuing circulation of this subtype in
birds that can serve as a source for the introduction of the HA with or
without the NA or internal protein gene segments, the proven
capability of H2 viruses to cause disease in humans, and the waning
Fig. 1. Level of replication of A/AA/6/60 (AA) viruses in the respiratory tract of mice
and ferrets. (A) Level of replication of AA ca and AA wt viruses in mice following i.n.
inoculation with 106 TCID50/mouse of AA wt (black bars), AA ca (white bars), or L-15
medium/mock-immunized (gray bars) on 3 dpi. Virus titers are expressed as mean±
SE log10 TCID50/g of tissue. The dashed horizontal line indicates the lower limit of
detection. ⁎0.01≤p≤0.05 (by Kruskal–Wallis). (B) Level of replication of AA ca and AA
wt viruses in ferrets following i.n. inoculation with 107 TCID50/ferret of AA wt (black
bars) or AA ca (white bars) on 3 dpi. Virus titers are expressed as mean±SE log10
TCID50/g (NT) or EID50/g (lung) of tissue. The dashed horizontal line indicates the
lower limit of detection.
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developing an H2 inﬂuenza vaccine candidate.
The cold-adapted (ca) inﬂuenza A/AA/6/60 (H2N2) (AA ca) virus
is the backbone for the live attenuated trivalent seasonal inﬂuenza
vaccine licensed in the United States. The AA virus was initially
isolated from throat washings on primary chick kidney tissue cultures
at 36 °C and adapted to growth at 25 °C through serial passage at
progressively lower temperatures (Maassab, 1967, 1969). The AA ca
virus displays important phenotypes that have been crucial to the
development of the virus for clinical use. The virus replicates
efﬁciently at 25 °C and 33 °C but does not replicate efﬁciently at
temperatures above 39 °C; these phenotypic traits have respectively
been designated cold-adapted (ca) and temperature-sensitive (ts)
phenotypes. In addition, the AA ca virus is attenuated in vivo (att
phenotype) and is restricted in replication in the respiratory tract of
mice and ferrets (Ali et al., 1982; Maassab et al., 1982; Murphy and
Coelingh, 2002). These phenotypes are speciﬁed by ﬁve mutations in
three gene (PB1, PB2, and NP) segments (Jin et al., 2003).
The seasonal live attenuated inﬂuenza virus vaccine (LAIV)
contains reassortant inﬂuenza A H1N1 and H3N2 viruses that derive
their internal protein genes from the AA ca virus and HA and NA from
circulating wild-type viruses. The AA ca donor virus and the 6:2
reassortant vaccine viruses possess phenotypic (ts, ca, and att) traits
stably conferred by the AA ca virus genes and the antigenic properties
conferred by the HA and NA proteins of the circulating viruses (Keitel
and Piedra, 1998; Maassab and Bryant, 1999; Maassab et al., 1982;
Murphy and Coelingh, 2002). Extensive preclinical and clinical trials
of the 6:2 reassortant viruses with HA and NA genes from different
H1N1 and H3N2 viruses preceded the licensure of LAIV. However,
only a small number of preclinical (Ali et al., 1982; Maassab et al.,
1982; Mak et al., 1982) and clinical (Kitayama et al., 1973) trials have
been conducted evaluating the AA ca (H2N2) virus as a vaccine. We
therefore evaluated the attenuation, immunogenicity, and efﬁcacy of
the AA ca (H2N2) virus inmice and ferrets to determine the suitability
of developing this virus as a vaccine candidate for use in the event of
an H2 pandemic.
Results
Replication in the respiratory tract of mice
The level of replication of the AA ca and AA wt viruses was
compared in the respiratory tract of mice (Fig. 1A). The mean virus
titer over days 2, 3, and 4 in the nasal turbinates of mice inoculated
with the AAwt virus was 106.2, 105.8, and 105.3 TCID50/g andwas 104.6,
104.4, and 105 TCID50/g in mice inoculated with the AA ca virus
(0.01≤pb0.05 by Kruskal–Wallis). Themean virus titer over days 2, 3,
and 4 in the lungs of mice inoculated with the AA wt virus was 108.1,
107.2, and 106.9 TCID50/g and was 104.1, 103.0, and 104.3 TCID50/g in
mice inoculated with the AA ca virus (0.01≤pb0.05 by Kruskal–
Wallis). Thus, the AA ca virus was restricted in replication in the
respiratory tract of mice compared to the AA wt virus.
Replication in the respiratory tract of ferrets
The level of replication of the AA ca and AA wt viruses in the
respiratory tract of ferrets is displayed in Fig. 1B. In the group
inoculated with the inﬂuenza AA ca virus (n=3), the virus was
detected in the nasal turbinates of all three ferrets and the mean virus
titer was 105.9 TCID50/g. However, virus was not detected (≤101.5
EID50/g) in the lungs demonstrating that the AA ca virus was
restricted in replication in the lower respiratory tract and was
therefore attenuated for ferrets. In contrast, in the ferrets inoculated
with the inﬂuenza AA wt virus (n=3), the mean virus titer was 106.0
TCID50/g in the nasal turbinates and 102.3±0.51 EID50/g in the lungs;
virus was detected in the lungs of 2 of 3 animals.Immunogenicity and efﬁcacy against homologous wt virus challenge
Mice
Among the mice that received a single dose of the AA ca virus
(Table 1), only 1 mouse demonstrated a substantial rise (postvaccine
titer 1:640) in HAI titer; the HAI titer of the remaining 3 mice ranged
from 1:20 to 1:40 and the geometric mean titer (GMT) for the group
was 57. Among the mice that received 2 doses of the AA ca virus
(Table 1), HAI antibodies were undetectable in 3 after the ﬁrst dose;
however, 1 mouse developed a modest detectable HAI titer after the
ﬁrst dose (postvaccine titer 1:20) and the GMT for the group was
therefore only 7. However, 4 weeks after two doses of the AA ca virus,
all 4 mice demonstrated a N4-fold rise in HAI titer (GMT: 113). As
expected, mock-immunized mice did not demonstrate any detectable
HAI antibodies. All four mice that received the AA wt virus were
euthanized due to increasing signs of distress on day 5 postinocula-
tion and thus a comparison of the immunogenicity and efﬁcacy of the
AA ca virus with that of the AA wt virus was not possible.
One or two doses of the AA ca virus provided complete protection
from replication in the respiratory tract of the homologous AA wt
Table 2
Geometric mean titers against heterologous H2 viruses as measured by HAI and
neutralization assays in postinfection mice and ferret sera.
Virus
administered
Assay Serum antibody titers in indicated species tested against
homologous and heterologous H2 viruses
FERRET MICE
AA Jap 57 Mal 78 Sw 06 AA Jap 57 Mal 78 Sw 06
AA wt HAIa 101 7 5 5 ND ND ND ND
Ntb 640 32 57 14 ND ND ND ND
AA ca HAIa 80 5 5 5 ND ND ND ND
Ntb 120 45 ND 25 80 14 17 14
Homologous antibody titers are expressed in bold.
ND=not done; AA=A/Ann Arbor/6/60; Jap 57=A/Japan/305/1957; Mal 78=A/
mallard/NY/6750/1978; Sw 06=A/Swine/MO/4296424/2006.
a Postinfection sera were pooled from 3 ferrets in the AA ca and AA wt groups.
Antibody was not detectable in sera collected on day 0 before inoculation.
b Postinfection sera were pooled from 3 ferrets in the AA wt and AA ca groups and 4
mice in the AA ca group. Antibody was not detectable (b5) on day 0 before inoculation
in any ferret or in 3 out of 4 mice (a titer of 20 was noted in the sera of 1 mouse before
inoculation with AA).
Table 1
Immunogenicity of the A/AA/6/60 (AA) ca vaccine against homologous wt virus in
mice.
Number of doses administered Geometric mean serum HAI titersa on
indicated days following vaccination




To determine immunogenicity of the AA ca vaccine in mice, we administered 50 μl of 1
or 2 doses of 106 TCID50 AA ca virus intranasally to groups of 4 mice and challenged
themwith 106 TCID50 AAwt 1month following the ﬁnal dose of vaccine. Control groups
were immunized with L-15 media or with the AA wt virus. Sera were collected before
immunization, at day 28 (after dose 1) and at day 54 (after dose 2).
a Geometric mean titers from groups of 4 mice. HAI antibodies were not detected in
sera from mock-immunized mice or in prevaccination sera from mice that were
received the AA ca vaccine virus.
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lenged with the AA wt virus, the mean viral titer in the nasal
turbinates was 105.9 TCID50/g and 106.6 TCID50/g in the lungs. In
contrast, 4 weeks after one or two doses of the inﬂuenza AA ca virus,
the AA wt challenge virus was not detected in either the nasal
turbinates or the lungs.
Ferrets
All ferrets immunized with either the AA ca virus or the AA wt
virus developed a ≥4-fold rise in serum HAI titer (GMT: 80 (in all
ferrets) and 101 (range 80–160), respectively) 1 month after
immunization. Antibody was not detectable in sera collected on day
0 before inoculation.Fig. 2. Efﬁcacy of the A/AA/6/60 (AA) ca virus against homologous challenge in mice
and ferrets. (A) Level of replication of AA wt viruses in mice immunized with 1 or 2
doses 106 TCID50/mouse of AA ca (white bars) or L-15 medium/mock-immunized
(gray bars) on day 3 after challenge with 106 TCID50/mouse of the AA wt virus. Virus
titers are expressed as mean±SE log10 TCID50/g of tissue. The dashed horizontal line
indicates the lower limit of detection. ⁎0.01≤p≤0.05 (by Kruskal–Wallis). (B) Level of
replication of AAwt viruses in ferrets immunized with 1 dose of 107 TCID50/ferret of AA
wt (black bars), AA ca (white bars), or L-15 medium/mock-immunized (gray bars) on
day 3 after challenge with 107 TCID50 of the AA wt virus. Virus titers are expressed as
mean±SE log10 TCID50/g (NT) or EID50/g (lung) of tissue. The dashed horizontal line
indicates the lower limit of detection. ⁎0.01≤p≤0.05 (by Kruskal–Wallis).When mock-immunized ferrets were challenged with the AA wt
virus (Fig. 2B), the mean virus titer in the nasal turbinates was 105.3
TCID50/g. In contrast, challenge virus was not detected in the nasal
turbinates of ferrets that had been immunized with either the AA ca
or wt virus 4 weeks earlier, indicating that both viruses provide
complete protection from replication of the AA wt challenge virus in
the upper respiratory tract of ferrets. However, virus was detected in
the lungs of only one mock-immunized animal and was not detected
in the lungs of any of the ferrets that had been immunized with the
inﬂuenza AA ca or wt viruses. These data indicate that the level of
replication of the AA wt virus in the lungs of ferrets is close to the
lower limit of detection and thus may not be a robust measure of
efﬁcacy in ferrets.
Immunogenicity and efﬁcacy against heterologous H2 virus challenge
Mice
Mice inoculatedwith theAA ca virus developed antibody responses
at a GMT of 80 (range 28–226) against the homologous AAwt virus as
measured by Nt assay (Table 2); however, signiﬁcant antibody
responses against heterologous wt H2 viruses were not detected.
Despite the low levels of antibody detected against heterologous
H2 viruses in the Nt assay, the AA ca virus provided signiﬁcant
protection from challenge with the heterologous H2 viruses in the
lower respiratory tract (p≤0.01 by Mann–Whitney U) of mice. In the
upper respiratory tract, the AA ca virus also provided signiﬁcant
protection (0.01bpb0.05 by Mann–Whitney U) from each of the
heterologous challenge viruses with the exception of mal 78wtwhich
did not replicate well in the upper respiratory tract of mice (Fig. 3A).
Ferrets
Ferrets inoculated with the AA ca virus developed an antibody
response at a GMT of 120 (range 32–226) against the homologous AA
wt virus as measured by Nt assay (Table 2) and a low level of cross-
reactivity against the heterologous wt H2 viruses. As with the cross-
protection studies inmice, no associationwas noted between the level
of antibody detected by Nt assay and the degree of protection
conferred from replication of heterologous H2 viruses (Fig. 3B). The
AA ca virus provided signiﬁcant protection from viral replication in
the lower respiratory tract (pb0.05 by Mann–Whitney U) of both Jap
57 wt and Sw 06 wt viruses.
Discussion
The recent emergence of the swine-origin H1N1 inﬂuenza virus
underscores the importance of planning for other inﬂuenza subtypes
Fig. 3. Efﬁcacy of the A/AA/6/60 (AA) ca virus against homologous and heterologous
challenge in mice and ferrets. (A) Efﬁcacy of 1 dose of 106 TCID50/mouse of AA ca
(white bars) or L-15 medium/mock-immunized (gray bars) in protection against
homologous and heterologous H2 virus challenge on day 3 after challenge with 105
TCID50/mouse of thewt virus. Virus titers are expressed as mean±SE log10 TCID50/g of
tissue. (B) Efﬁcacy of 1 dose of 107 TCID50/ferret of AA ca (white bars) or L-15 medium/
mock-immunized (gray bars) in protection against homologous and heterologous H2
virus challenge on day 3 after challenge with 106 TCID50/ferret of the wt virus. Virus
titers are expressed as mean±SE log10 TCID50/g of tissue. The dashed horizontal line
indicates the lower limit of detection. ⁎0.01≤p≤0.05 (by Kruskal–Wallis); ⁎⁎p≤0.01
(by Kruskal–Wallis).
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pandemic in humans and immunity in the population is waning, thus,
the development of an H2 inﬂuenza vaccine should represent a
priority in pandemic inﬂuenza preparation. Although the likelihood of
an exact match between a stockpiled vaccine and a pandemic virus is
low, the development and stockpiling of an inﬂuenza vaccine
candidate that demonstrates protection against heterologous chal-
lenge may be critical in mitigating the early impact on public health of
an emerging pandemic. A rational initial H2 inﬂuenza candidate is the
AA ca virus that is currently used as the backbone for the reassortant
inﬂuenza A viruses contained in the seasonal LAIV licensed in the
United States. While there is now substantial clinical experience with
LAIV, very limited information is available from preclinical and clinical
studies evaluating the complete AA ca (H2N2) virus. Our goal was to
establish the safety, immunogenicity, and efﬁcacy of the AA ca virus in
mice and ferrets to determine the suitability of this virus as an H2
vaccine for humans in the event of a reemergence of H2 viruses in
humans.
In mice, the AA ca virus was attenuated compared with the AA wt
virus. Following two doses of the AA ca vaccine virus, all immunized
mice developed a N4-fold rise in HAI antibody and were protected
against homologous virus challenge in both the upper and lower
respiratory tract. Due to increasing signs of clinical illness (e.g., micewere hunched and scruffy), all mice immunized with the AA wt virus
were euthanized on day 5 postinoculation and thus a comparison to
the immunogenicity and efﬁcacy of the AA ca virus was not possible.
Following one dose of the AA ca virus, only one immunized animal
developed a signiﬁcant antibody titer; however, all four mice were
protected against homologous virus challenge, suggesting that a rise
in HAI antibody is not an accurate correlate of protection and that
other potential mechanisms such as mucosal and cellular immunity
contribute to protection. The lack of correlation between serum
antibody response and protection against challenge has previously
been noted in clinical trials of live attenuated seasonal inﬂuenza
vaccines (Belshe et al., 2000, 2004) as well as in preclinical studies
with live attenuated H5 and H7 pandemic inﬂuenza vaccines (Joseph
et al., 2008; Suguitan et al., 2006); this discrepancy suggests that the
current techniques for assessing the immune response to these
vaccines may not accurately reﬂect protection against inﬂuenza
(Eichelberger et al., 2008). Assays that assess other components of the
immune response, including the cellular immune response, secretory
IgA, antibody directed against other proteins including theM2 protein
or the neuraminidase may be needed and will be addressed in future
studies.
In ferrets, the AA ca virus was attenuated and immunogenic.
Following homologous virus challenge, the AA wt virus was not
detected in the upper or lower respiratory tract of any of the animals
immunized with either the AA ca or AA wt virus. However, the AA wt
challenge virus was detected in the lungs of only 1 of 3 mock-
immunized animals. The low level of replication of the AA wt virus in
the lower respiratory tract of ferrets has been noted previously
(Suguitan et al., 2006), suggesting that the replication of the AA wt
virus may not be a robust measure of efﬁcacy in this species.
In mice, despite a lack of cross-reactivity against heterologous H2
viruses as measured by Nt assay, immunization with the AA ca virus
conferred protection against replication of several heterologous H2
viruses in both the upper respiratory and the lower respiratory tract.
Similarly, in ferrets, despite the low level of cross-reactivity as
measured by both HAI and Nt assay, immunization with the AA ca
virus conferred complete protection from heterologous H2 virus
challenge in the lower respiratory tract. These observations suggest
that serum antibody is not an accurate correlate of protection and that
further characterization of the relationship between antibody re-
sponse and protection from replication of challenge viruses is needed.
Future studies may be necessary to determine whether other avian or
human H2 viruses are capable of either eliciting a more broadly cross-
reactive antibody response than the AA ca virus.
In summary, we have demonstrated that the AA ca virus is safe,
attenuated, and immunogenic in mice and ferrets. We have also
observed that the AA ca virus is able to confer protection from
homologous and heterologous H2 virus challenge. These studies
suggest that the AA ca virus warrants evaluation as a potential H2
pandemic vaccine candidate in phase I clinical trials.
Materials and methods
Viruses
The wild-type A/Swine/MO/4296424/2006 (H2N3) (Sw06 wt)
virus was kindly provided by Drs. Adolfo Garcia-Sastre (Mt. Sinai
School of Medicine, New York, NY) and Juergen Richt (ARS-USDA,
Ames, IA). The AA ca virus from MedImmune was completely
sequenced and conﬁrmed to possess the mutations in the PB2, PB1,
PA, and NP gene segments that confer the phenotypic properties of
the AA ca donor virus. Wild-type virus stocks were propagated in the
allantoic cavity of 9- to 11-day-old embryonated speciﬁc pathogen-
free (SPF) hens' eggs (Charles River Laboratories, Franklin, CT) at
37 °C and ca viruses at 33 °C. The 50% tissue culture infectious dose
(TCID50) titers were determined in Madin-Darby canine kidney
113G.L. Chen et al. / Virology 398 (2010) 109–114(MDCK) cells (ATCC, Manassas, VA). Wild-type and cold-adapted
viruses were incubated at 37 °C or 33 °C and titers were determined
at day 4 or 6, respectively, following inoculation. The 50% egg
infectious dose (EID50) titers were determined in 9- to 11-day-old
speciﬁc pathogen-free (SPF) embryonated eggs (Charles River
Laboratories, Franklin, CT). Viral titers were calculated using the
method of Reed and Muench (1938). All experiments were
conducted in BSL3 containment laboratories at the National Institutes
of Health approved for use by the Centers for Disease Control and
Prevention.
Animals
Four- to six-week-old female BALB/c mice (Taconic Farms, Inc.,
Germantown, NY) were used in all mouse experiments. Seven-week-
old male ferrets (Triple F Farms, Sayre, PA) were used in the ferret
studies. Animal experiments were approved by the National Institutes
of Health Animal Care and Use Committee.
Evaluation of the level of replication in the respiratory tract of mice and
ferrets
To evaluate the level of replication of the AA ca virus in the
respiratory tract of mice, we administered 50 μl of 106 TCID50 of the
inﬂuenza AA ca virus or the inﬂuenza AA wt virus or 50 μl of L-15
intranasally to 3 groups of 12 BALB/c mice lightly anesthetized with
isoﬂurane. On days 2, 3, and 4 following inoculation, lungs and nasal
turbinates were harvested from 4 mice in each group, weighed, and
homogenized in L-15 medium (Invitrogen-GIBCO) containing antibi-
otic–antimycotic (penicillin, streptomycin, and amphotericin B)
(Invitrogen-GIBCO) to make 5% (wt./vol.) (nasal turbinates) or 10%
(wt./vol.) (lungs) tissue homogenates. Tissue homogenates were
clariﬁed by centrifugation and titrated in 24- and 96-well tissue
culture plates containing MDCK cell monolayers.
To evaluate the level of replication of the AA ca virus in the
respiratory tract of ferrets, 200 μl of 107 TCID50 of the inﬂuenza AA ca
virus or AA wt virus was administered intranasally to 2 groups of 3
ferrets lightly anesthetized with isoﬂurane. On day 3 following
inoculation, lungs and nasal turbinates were harvested from all 6
ferrets. Viral titers in the nasal turbinates were determined by
titration on MDCK cells and viral titers in the lungs were determined
by titration in 9- to 11-day-old SPF embryonated eggs.
Immunogenicity against homologous and heterologous H2 viruses
Antibody titers in postinfection mouse and ferret sera were
determined by hemagglutination–inhibition (HAI) assays. Sera were
treated overnight with receptor-destroying enzyme (Denka Seiken
Co., Ltd., Tokyo, Japan) and were subsequently tested by standard
methods using 4 HA units of virus and a 0.5% suspension of turkey red
blood cells, as previously described (Stephenson et al., 2003). HAI
titers were recorded as the reciprocal of the highest dilution of the
serum that completely inhibited agglutination of erythrocytes by 4 HA
units of the virus. Group HAI titers were expressed as geometric mean
titers (GMT).
Neutralizing antibody titers in pre- and postimmunization sera
were determined in a virus neutralization (Nt) assay. Serial two-fold
dilutions of heat-inactivated serum were prepared starting from a
1:10 or 1:20 dilution. Equal volumes of serum and virus were mixed
and incubated for 60 minutes at room temperature. The residual
infectivity of the virus–serum mixture was determined in MDCK cells
in four replicates for each dilution. Neutralizing antibody titers were
log2-transformed and deﬁned as the reciprocal of the highest dilution
of serum that completely neutralized the infectivity of 100 TCID50 of
the virus as determined by the absence of CPE at day 4 for wt viruses
and at day 6 for ca viruses.Efﬁcacy against homologous challenge
Mice
To determine efﬁcacy of the AA ca vaccine against challenge
with the homologous AA wt virus in mice, we administered 50 μl of
1 or 2 doses of 106 TCID50 AA ca virus intranasally to groups of 4
mice lightly anesthetized with isoﬂurane and challenged them with
106 TCID50 AA wt 1 month following the ﬁnal dose of vaccine.
Control groups were immunized with L-15 medium or with the AA
wt virus. In mice, nasal turbinates and lungs were harvested 3 days
following challenge and virus titers were determined in MDCK cells
as described above.
Ferrets
To evaluate the efﬁcacy of the AA ca vaccine in ferrets, a single
dose of 200 μl of 107 TCID50 AA ca virus was administered intranasally
to 9 (7-week-old) ferrets lightly anesthetized with isoﬂurane. Control
groups were mock-immunized with L-15 medium (mock-immunized
group) or were infected with the AA wt virus. The ferrets were then
challenged with 107 TCID50 of the AA wt virus 4 weeks following
vaccination. On day 3 following challenge, nasal turbinates as well as
the left and right lower lobes of the lung were harvested from all
ferrets. Virus titers in the nasal turbinates were determined in MDCK
cells; virus titers in the lower respiratory tract were determined in
embryonated SPF eggs.
Efﬁcacy against heterologous challenge
Mice
To determine the efﬁcacy of the AA ca vaccine against heterolo-
gous challenge in mice, three heterologous wild-type H2 viruses were
selected: A/Mallard/NY/6750/78 (H2N2) (Mal78 wt), A/Japan/305/
57 (H2N2) (Jap57 wt) or Sw06 wt. We intransally administered 50 μl
of 1 dose of either 106 TCID50 AA ca or L-15 medium (mock-
immunized group) to 32 mice (4 mice per group) lightly anesthetized
with isoﬂurane and challenged with 50 μl of 105 TCID50 AA wt, Mal78
wt, Jap57wt or Sw06 wt intranasally 1 month following the ﬁnal dose
of vaccine. Nasal turbinates and lungs were harvested 3 days
following challenge and virus titers were determined in MDCK cells
as described above.
Ferrets
In ferrets, we administered 200 μl of 107 TCID50 AA ca, AA wt or
L-15 medium (mock-immunized group) intranasally to 9 (7-week-
old) ferrets lightly anesthetized with isoﬂurane. These ferrets were
then challenged with 200 μl of 106 TCID50 of AA wt, Jap57 wt or Sw06
wt intranasally 4 weeks following vaccination. Nasal turbinates and
lungs were harvested 3 days following challenge. Virus titers in the
nasal turbinates were determined in MDCK cells; virus titers in the
lungs were determined in embryonated SPF eggs.
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